Estrogen receptor (ER) expression in lung tumors suggests that estrogens may play a role in the development of lung cancer. We evaluated the role of hormone-related factors in determining risk of non-small-cell lung cancer (NSCLC) in women. We also evaluated whether risk factors were differentially associated with cytoplasmic ER-␣ and/or nuclear ER-␤ expression-defined NSCLC in postmenopausal women.
INTRODUCTION
Lung cancer in women has several different characteristics than lung cancer in men, with women more likely to have adenocarcinomas of the lung, higher risk in never smokers, 1 higher levels of polycyclic aromatic hydrocarbon-DNA adducts at any given level of smoking, 2 higher levels of expression of the gene encoding CYP1A1, 2,3 more frequent G:C to T:A transversions in p53, 4 and more frequent epidermal growth factor receptor mutations 5 than men. These findings led to investigation into the role of estrogens in determining lung cancer risk. Epidemiologic evidence supporting a role for reproductive and estrogen use history in lung cancer development has been somewhat inconsistent, with reports of increased risk of adenocarcinomas with use of estrogen replacement therapy 6, 7 , as well as reduced risk with use of oral contraceptives (OC) and hormone replacement therapy (HRT). [8] [9] [10] Research focused on the role of estrogens and lung cancer has extended into investigations of estrogen receptors (ER). Two subtypes of the ER have been described, ER-␣ and ER-␤, both of which have a high affinity for estradiol. Several studies suggest frequent expression of ER in lung tumors. [11] [12] [13] [14] [15] Nuclear ER-␤ is present in the normal lung [16] [17] [18] and is abundant in lung tumor tissue. 15, 19 There is less consensus on the occurrence of ER-␣ in the lung, although it seems that the ER-␣ in the lung may be present in a fragmented, non-nuclear form.
Given the potential for estrogen to interact with ERs in the lung and its effect on cell growth, we evaluated the role of reproductive factors and hormone use in determining risk of non-small-cell lung cancer (NSCLC) in women in a large population-based study. We further studied these risk factors for their association with cytoplasmic ER-␣-and nuclear ER-␤-defined NSCLC with the hypothesis that estrogen use affects risk differentially for ER-positive and ER-negative tumors.
PATIENTS AND METHODS

Study Participants
Patients were enrolled through the population-based Metropolitan Detroit Cancer Surveillance System, a participant in the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Women aged 18 to 74 years diagnosed with primary NSCLC in Wayne, Macomb, and Oakland counties between November 1, 2001 and October 31, 2005 were eligible to participate. Ascertainment was originally focused on adenocarcinoma histology but was broadened after November 1, 2004 to include all NSCLC histologic types because many histologic diagnoses at the time of rapid participant ascertainment were not more specific. Seventy-one percent of patients had adenocarcinoma histology, 8% had squamous cell carcinoma, 3% had large-cell carcinoma, and 17% had NSCLC unspecified, reflecting this sampling method.
Five hundred eighty-five women (54%) completed an in-person interview. The highly fatal nature of lung cancer and the likelihood of a late-stage diagnosis meant that many women were too ill (n ϭ 135) to participate. We could not locate a working phone number for another 89 women, and 270 women refused. Women self-reporting race other than African American or white (n ϭ 16) and women with an unknown menstrual status (n ϭ 26) were excluded. Fifty-five patients with a previous history of breast cancer were excluded because of the associations between reproductive factors and breast cancer risk, thus ensuring that associations detected were not driven by differences in breast cancer risk factors between patient cases and controls. In total, 488 women were available for analysis.
Population-based controls were identified through random digit dialing. Control women were frequency matched to patient cases on race and 5-year age group. Of the households willing to complete the brief eligibility screening questionnaire, 70.6% (n ϭ 538) participated. Twenty-two controls reporting a previous breast cancer diagnosis, 11 reporting race other than African American or white, and seven with unknown menstrual status were excluded, leaving 498 controls for analysis.
Data and Biospecimen Collection
All local institutional and review boards approved this study. Informed consent was obtained from each participant before study participation. Inperson interviews were conducted to collect demographic information, smoking history, health history, reproductive history, and environmental tobacco smoke exposure. Medical history included self-report of physician diagnoses of asthma, emphysema, allergies, pneumonia, bronchitis, chronic obstructive pulmonary disease, tuberculosis, and cancer. Emphysema, chronic obstructive pulmonary disease, and chronic bronchitis were combined to create a broad chronic obstructive lung disease variable. Diagnoses reported within 1 year of lung cancer diagnosis (for patient cases) or interview (for the controls) were excluded. Reproductive data collected included age menses began and ended, menstrual cycle length, number of pregnancies, and number of children born. Dates and dosages for OC use and HRT were collected. Estrogen only, estrogen combined with progesterone, progesterone only, and unknown HRT formulations were included as HRT use in analyses. Duration of OC and HRT use was categorized in quartiles based on use among the controls. Detailed dose data for women taking HRT were available for 51.1% of patient cases and 50.6% of controls. A cumulative lifetime estrogen exposure measure, calculated by multiplying dose by months of use and summing over the lifetime (mg ϫ months), was analyzed in quartiles based on data from controls. Family history of lung cancer was coded as yes or no based on the detailed first-degree family history information.
Immunohistochemistry
Lung tumor samples from women who had undergone surgical treatment were available for 241 patients. The methods for evaluating nuclear ER-␤ expression have been discussed previously. 19 Five-micron sections of lung tumor tissue were stained using the antibody ER-␤-MCA1974S (Serotec, Oxford, United Kingdom), which is raised against the C terminus of the ␤1 isoform of ER-␤. Positive controls for ER-␤ included benign hyperplastic prostate tissue, breast tissue, and granulosa cell carcinoma of the ovary. Fragmented, cytoplasmic ER-␣ was assayed using an antibody to the C terminus (Santa Cruz sc-543; Santa Cruz Biotechnology, Santa Cruz, CA). Breast cancer tissue served as a positive control for ER-␣. Results for ER-␣ and ER-␤ were each scored separately for intensity and extent of positivity. Intensity was scored in an ascending 1 to 3 scale. Extent of positivity was defined by the percentage of positive tumor cells in the sample, as follows: 1 for Յ 10%, 2 for 11% to 49%, and 3 for Ն 50%. Positive results were measured conservatively as samples with at least weak (1ϩ) staining in Ն 10% of tumor cells. The pathologist was blinded to all patient characteristics.
Statistical Analysis
Comparisons of dichotomous risk factors were made between patient cases and controls using 2 tests; comparisons of means were conducted using Student's t tests. Multivariate unconditional logistic regression models were used to estimate odds ratios (ORs) and 95% CI. Initial models were based on nonreproductive and nonhormone-related factors to identify a set of independent, significant (P Ͻ .05) risk factors to be included in all subsequent models. These factors included age (continuous variable), race, education, pack-years of smoking (continuous variable), history of chronic obstructive lung disease, current body mass index (continuous variable), years exposed to passive smoke in the workplace (continuous variable), and family history of lung cancer. Each reproductive and hormone-related variable was introduced individually into this model to test for statistical significance. Stepwise logistic models were then created using all reproductive and hormone-related variables that were significant at P Ͻ .1 in the previous models described. Any factor with a P Ͻ .1 was retained in the model. These models were also used to test for associations between risk factors and NSCLC development defined by ER-␣ and ER-␤ expression. Stratified analyses were used to evaluate the effects of race, age at diagnosis, histologic type, HRT type, and smoking history. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Patient cases and controls differed in age (1.7 years), ever smoking, mean pack-years among smokers, years of environmental tobacco smoke exposure, education, body mass index at the time of interview, personal history of chronic obstructive lung disease, and first-degree family history of lung cancer (Table 1) .
Reproductive and hormone-related factors are listed in Table 2 . Most women were postmenopausal. Patient cases were significantly younger than controls at menopause by 1.8 years and had significantly fewer average years of menses (2 years). Age at first live birth was significantly younger for both pre/perimenopausal and postmenopausal patient cases than controls. Pre/perimenopausal patient cases also had more children than controls. OC use did not differ between patient cases and controls for either the ever/never category or quartile of use in either menopausal category. Ever use of HRT differed between postmenopausal patient cases and controls, but among women using HRT, duration of HRT use, estrogen dose, and type of HRT were not different in univariate analyses. Infertility medication use, birth control injections, and hormone use other than HRT were not associated with risk of NSCLC in any group of women (data not shown).
None of the reproductive or hormone use variables predicted risk of NSCLC in all women combined based on multivariable models (Table 3) . Among pre/perimenopausal women, both the number of pregnancies (OR ϭ 1.36; 95% CI, 1.07 to 1.74) and number of children (OR ϭ 1.64; 95% CI, 1.14 to 2.36) were associated with modest increases in risk. Ever use of OCs was associated with a large OR, but Abbreviations: NSCLC, non-small-cell lung cancer; SD, standard deviation; BMI, body mass index; GED, General Educational Development high school equivalency degree; ETS, environmental tobacco smoke.
‫ء‬
Missing for two patient cases and three controls. †Quit smoking at least 2 years before diagnosis (patient cases) or interview (controls). Abbreviations: NSCLC, non-small-cell lung cancer; SD, standard deviation; OC, oral contraceptive; HRT, hormone replacement therapy.
P value calculation excludes unknown responses. †Missing for one postmenopausal patient case. ‡Menstrual cycle length was collected only for women with usually or always regular cycles and, therefore, is missing for 10 pre-or perimenopausal patient cases, 12 pre-or perimenopausal controls, 115 postmenopausal patient cases, and 80 postmenopausal controls.
§Missing for two postmenopausal patient cases and three postmenopausal controls. ʈMissing for three postmenopausal patient cases and three postmenopausal controls. ¶Missing for one postmenopausal control. #Lifetime estrogen doses for HRT were not available for four pre-or perimenopausal patient cases, five pre-or perimenopausal controls, 110 postmenopausal patient cases, and 120 postmenopausal controls.
this finding did not reach statistical significance (P ϭ .06) and was based on small numbers. Duration of HRT use (OR ϭ 0.88; 95% CI, 0.78 to 1.00; P ϭ .04) was associated with a decreased risk of NSCLC in postmenopausal women. There were no significant differences in risk associated with combined HRT or estrogen-only therapy versus nonusers. Analyses were also conducted after stratification by age at diagnosis, race, and smoking history in postmenopausal women only Abbreviations: NSCLC, non-small-cell lung cancer; OR, odds ratio; OC, oral contraceptive; HRT, hormone replacement therapy.
Adjusted for age at diagnosis/interview (continuous), race (white or African American), pack-years (continuous), family history of lung cancer (yes or no), current body mass index (continuous), personal history of chronic obstructive lung disease (yes or no), years exposed to passive smoke in the workplace (continuous), and education level (less than high school, high school or General Educational Development high school equivalency degree, or more than high school). Abbreviations: OC, oral contraceptive; HRT, hormone replacement therapy; NSCLC, non-small-cell lung cancer; OR, odds ratio.
( Table 4 ). There was evidence of reduced risk with increasing duration of OC use in postmenopausal women having 1 to 20 pack-years of smoking exposure (OR ϭ 0.64; 95% CI, 0.46 to 0.88). Although duration of HRT use was associated with reduced risk among all postmenopausal women, only the findings for women diagnosed before age 55 years were statistically significant (OR ϭ 0.70; 95% CI, 0.49 to 0.99). As age at diagnosis increased, the role of HRT use in determining risk of NSCLC diminished. There was a significant trend toward reduced risk with increasing months of HRT use in the youngest age group (P ϭ .05) and a similar, but not statistically significant, trend in women 55 to 64 years of age (P ϭ .08; Table 5 ). Multivariate logistic regression was also performed for ER-␣-and ER-␤-defined NSCLC (Table 6 ). Sixty-six percent of lung tumors were positive for cytoplasmic ER-␣ expression, and 48.6% were positive for nuclear ER-␤ expression. Thirty-nine percent of tumors expressed both ERs, whereas 12% were negative for expression of both. 
DISCUSSION
This study demonstrates increased NSCLC risk associated with numbers of pregnancies and children in pre/perimenopausal women and an inverse association between exogenous estrogen exposure and NSCLC risk in postmenopausal women. Reductions in risk were associated with increasing duration of HRT use in postmenopausal women and OC use in postmenopausal smokers of 1 to 20 pack-years. Inconsistent findings have been reported for associations between pregnancies and lung cancer risk. Our findings among pre/perimenopausal women are based on small numbers and should be interpreted with caution. Schabath et al 9 found a reduction in lung cancer risk among HRT users (OR ϭ 0.66; 95% CI, 0.51 to 0.89), but duration of use data were unavailable. Kreuzer et al 8 found a nonsignificant reduction in lung cancer risk among HRT users (OR ϭ 0.83; 95% CI, 0.64 to 1.09), along with a reduction in risk with at least 7 years of HRT use (OR ϭ 0.59; 95% CI, 0.37 to 0.93), which are findings similar to those in our study. They found a significant reduction in risk with OC use (OR ϭ 0.69; 95% CI, 0.51 to 0.92), but there were no associations between most reproductive factors and lung cancer risk. Wu et al 10 reported decreased risk of adenocarcinoma associated with 2 or more years of OC use (OR ϭ 0.6; 95% CI, 0.2 to 0.8). Conversely, Taioli and Wynder 6 found an interaction between HRT and smoking, suggesting that women who smoked and used estrogen replacement therapy were at 33-fold increased risk of developing adenocarcinoma compared with nonsmoking women not using estrogen replacement therapy. Increased risk of lung cancer among HRT users was also reported in a cohort of never smoking women in Japan (OR ϭ 2.4; 95% CI, 1.07 to 5.40). 7 None of the published studies had information on ER status in tumor tissue. The most significant findings we report are in the youngest women using HRT for the longest duration. This group of women may represent a unique subset with underlying hormonal conditions potentially related to HRT use and lung cancer risk.
We show a significant decrease in NSCLC risk among HRT users, with evidence of a duration-dependent effect, for cytoplasmic ER-␣-and/or nuclear ER-␤-positive NSCLC. Sixty-six percent and 49% of our lung tumors stained positive for cytoplasmic ER-␣ and nuclear ER-␤, respectively. These percentages are consistent with other studies. [19] [20] [21] [22] Several studies have shown increased ER-␣ and ER-␤ expression in lung tumor tissue versus adjacent normal tissue, [19] [20] [21] 23 with the same localization pattern reported here. 15 To our knowledge, this is the only study with enough patient cases and collection of reproductive and hormone use data to evaluate lung cancer risk associated with exogenous estrogen use by ER tumor expression.
Both nuclear and cytoplasmic localization of ER-␣ and ER-␤ have been reported. 24 Estrogens and ERs play important roles in regulating growth and differentiation of various tissues by acting Abbreviations: NSCLC, non-small-cell lung cancer; HRT, hormone replacement therapy; OR, odds ratio; SD, standard deviation.
‫ء‬
Adjusted for age at diagnosis/interview (continuous), race (white or African American), pack-years (continuous), family history of lung cancer (yes or no), current body mass index (continuous), personal history of chronic obstructive lung disease (yes or no), years exposed to passive smoke in the workplace (continuous), and education level (less than high school, high school or General Educational Development high school equivalency degree, or more than high school) through at least two different ligand-activated mechanisms. One mechanism involves binding of a ligand to ER nuclear receptors, altering transcription by binding to the estrogen-response element or to transcription factors in the promoter regions of target genes.
25,26
Nuclear ER-␣, in the presence of estrogen, activates transcription at AP-1 sites, whereas nuclear ER-␤ bound to estrogen results in inhibition of transcription. 27 The finding of decreased risk of tumors expressing nuclear ER-␤ with HRT use fits in this pathway (ie, use of HRT is associated with increased levels of estrogen, which binds to ER-␤ in the lung, reducing transcription and thus reducing cell growth). However, estrogen action in the lung is not likely to be explained so simply. Dose and duration of HRT use is only an indirect measure of lung tissue exposure to estrogen. Actual estrogen level in lung tissue, both from endogenous and exogenous estrogens, was not measured.
The role of cytoplasmic ER-␣ is less clear. 24 Hershberger et al 22 suggest that cytoplasmic ER-␣ is unlikely to be a transcriptional mediator in response to estrogen in NSCLC. However, Stabile et al 15 showed that estrogen stimulates transcription 1.5-to two-fold in lung cancer cell lines expressing cytoplasmic ER-␣ and nuclear ER-␤. Alternative pathways of estrogen action in the lung have been demonstrated. In NSCLC cell lines, estradiol promotes an association between ER-␤ and GRIP1/TIF2 coactivators that modifies gene expression 22 and stimulates cell growth. 22 ,28 E-cadherin and Id-2 levels increase, whereas antiestrogen treatment using faslodex (ICI 182780) decreased expression of these proteins when ER-␤-expressing cell lines were treated with estradiol. These data suggest that lung cells respond to estrogen and estrogen alters growth.
A potential second mechanism of action involves cross-talk between ERs and growth factor receptor-mediated pathways in the plasma membrane. 29 Yu et al 30 found that estradiol and tamoxifen citrate stimulate genomic events (through increased expression of c-myc) and nongenomic events (through rapid cytoplasmic activation of p44/42 mitogen-activated protein kinase) via ER-␣ and ER-␤ mechanisms in pulmonary lymphangioleiomyomatosis cells. Epidermal growth factor receptor protein is downregulated in response to estrogen and upregulated by antiestrogens in these same cell lines.
31
Estrogen and ER mRNA and protein expression in normal lung and lung tumor tissue may also affect mRNA expression in the lung of phase I and phase II enzymes involved in metabolism of tobacco smoke carcinogens. In nontumor lung tissue, ER-␤ expression has been positively correlated with CYP1B1 expression (P ϭ .024) and NQO1 expression (P ϭ .001) in women and positively correlated with GSTT1 expression in men (P ϭ .025). 32 In lung tumor tissue, ER-␤ expression was negatively correlated with GSTT1 expression in women (P ϭ .005), and ER-␣ expression was positively correlated with NQO1 expression in men (P ϭ .001). In the same case series (n ϭ 45), plasma estradiol was positively correlated with GSTT1 expression in men (P ϭ .015). Given that multiple pathways of estrogen action exist, much additional work is needed to determine mechanisms of action of estrogen in the lung.
The current study uses a large population-based sample but has some limitations. HRT use is based on individual recollection, but the potential for recall bias should be minimal because HRT use among postmenopausal women is primarily current or recent. Recall bias may be greater for OC use, but recall is unlikely to occur differentially for patients and controls. Recall bias was also minimized by the use of a calendar to record significant events in a woman's life. Another potential limitation is the somewhat low response rate for interview and tumor retrieval common to most population-based lung cancer studies because of the high patient fatality rate and limited surgical intervention. Therefore, study results may only be applicable to a subset of all women with NSCLC and most specifically to adenocarcinomas. Nevertheless, to our knowledge, this is the first study to demonstrate associations between hormone use and lung cancer risk that vary by tumor ER expression. Overall, we have shown an inverse relationship between HRT use and NSCLC risk in postmenopausal women. This association is strongest for ER-positive NSCLC. The multiple pathways of estrogen action, variation in response to estrogen by ER-␣ and ER-␤ in lung tissue, and the interplay between estrogen, ER expression, smoking, and metabolic enzyme expression in the lung underscore the complexity of investigations into the role of exogenous estrogen in lung cancer risk. However, untangling tumor characteristics holds the promise of targeted interventions and treatments for this disease.
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